New obesity drug enters early human safety testing
NCT ID NCT07225556
First seen Nov 06, 2025 · Last updated Jun 17, 2026 · Updated 30 times
Summary
This early-stage study is testing a new medicine called LY4167586 in people who are overweight or have obesity but are otherwise healthy. The main goal is to see if the drug is safe and how the body processes it after a single dose. About 84 participants will be randomly assigned to receive either the drug or a placebo, and the study lasts around 7 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fortrea Clinical Research Unit
RECRUITINGMadison, Wisconsin, 53704, United States
Contact Phone: •••-•••-••••
Contact
-
Lilly Centre for Clinical Pharmacology
RECRUITINGSingapore, 138623, Singapore
Contact Phone: •••-•••-••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.